Long-term effectiveness and safety of lacosamide as adjunctive therapy in children and adolescents with refractory epilepsy: a real-world study.
Adolescents
Children
Effectiveness
Lacosamide
Refractory epilepsy
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
20 05 2023
20 05 2023
Historique:
received:
04
07
2022
accepted:
26
04
2023
medline:
22
5
2023
pubmed:
21
5
2023
entrez:
20
5
2023
Statut:
epublish
Résumé
The effectiveness and tolerability of lacosamide (LCM) among Chinese children and adolescents with refractory epilepsy has not yet been established. Therefore, the objective of this study was to assess the effectiveness and tolerability of LCM among children and adolescents with refractory epilepsy in Xinjiang, Northwest China. Effectiveness was assessed by measuring changes in seizure frequency at 3, 6 and 12 months compared with baseline. Patients that achieved ≥ 50% reduction in the frequency of all seizures per month, relative to baseline, were considered to be responders. 105 children and adolescents with refractory epilepsy were enrolled in the study. The responder rates were 47.6%, 39.2%, and 31.9%, respectively at 3, 6, and 12 months. Seizure freedom rates were 32.4%, 28.9%, and 23.6% at 3, 6, and 12 months, respectively. The retention rates at 3, 6, and 12 months were 92.4%, 78.1%, and 69.5%, respectively. The maintenance dose of LCM within the responder group (8.2 ± 4.5 mg·kg This real-world study of children and adolescents validated that LCM was both an effective and well-tolerated treatment option for the treatment of refractory epilepsy.
Identifiants
pubmed: 37210552
doi: 10.1186/s12887-023-04039-5
pii: 10.1186/s12887-023-04039-5
pmc: PMC10199619
doi:
Substances chimiques
Lacosamide
563KS2PQY5
Anticonvulsants
0
Acetamides
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
249Informations de copyright
© 2023. The Author(s).
Références
Epilepsy Res. 2018 Sep;145:51-54
pubmed: 29890341
Expert Rev Neurother. 2009 Jan;9(1):33-42
pubmed: 19102666
Epilepsia. 2018 May;59(5):1004-1010
pubmed: 29663335
Epilepsy Behav. 2018 Feb;79:130-137
pubmed: 29287216
Seizure. 2020 Jul;79:75-79
pubmed: 32422546
Eur J Paediatr Neurol. 2012 Jan;16(1):15-9
pubmed: 21924653
Neurology. 2019 Sep 17;93(12):e1212-e1226
pubmed: 31462582
J Child Neurol. 2019 Feb;34(2):68-73
pubmed: 30484357
Seizure. 2015 Feb;25:1-17
pubmed: 25645629
J Neurol Neurosurg Psychiatry. 2020 Oct;91(10):1067-1075
pubmed: 32817358
J Paediatr Child Health. 2019 Feb;55(2):194-198
pubmed: 30051539
Epilepsia Open. 2021 Sep;6(3):618-623
pubmed: 34265173
Epilepsy Behav. 2021 Sep;122:108128
pubmed: 34229159
Epilepsia. 2019 Dec;60(12):2437-2447
pubmed: 31755090
Epilepsy Behav. 2019 May;94:178-182
pubmed: 30959275
Mol Pharmacol. 2015 Jul;88(1):141-50
pubmed: 25848093
Epilepsy Behav. 2015 Nov;52(Pt A):119-27
pubmed: 26414341
Epilepsia. 2017 Jan;58(1):27-41
pubmed: 27864845
Acta Neurol Belg. 2019 Sep;119(3):423-430
pubmed: 30840220
Epilepsia. 2010 Jun;51(6):1069-77
pubmed: 19889013